MedPath

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis

Phase 1
Recruiting
Conditions
Osteoarthritis Shoulder
Shoulder Pain
Interventions
Biological: Micro Fragmented Adipose Tissue
Biological: Corticosteroid injection
Registration Number
NCT04929951
Lead Sponsor
Stanford University
Brief Summary

This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.

Detailed Description

This study will be a randomized controlled trial to compare outcomes between intra-articular injection of Micro Fragmented Adipose Tissue and intra-articular injection of corticosteroid in patients with mild to moderate osteoarthritis of the shoulder. Micro Fragmented Adipose Tissue will be harvested at the subcutaneous tissue by lipoaspiration. Once fat tissue is obtained, it will be processed with minimal manipulation in the clinic room.

To be considered for participation in this study, patients must have radiographic evidence of mild to moderate osteoarthritis of the shoulder (glenohumeral joint). In addition, patients must meet several inclusion/exclusion criteria to be randomized and included in this study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Age between 25 and 75 years-old
  • Diagnosis of pre-existing osteoarthritis of the glenohumeral joint
  • Working understanding of the English language and able to fully understand the procedure
  • Capable of providing informed consent
  • Able to complete online, in-person or phone surveys for the purposes of follow-up
  • Capable of understanding pre- and post-procedure care instructions
  • Ambulatory at baseline
  • Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and/or injections.
Read More
Exclusion Criteria
  • Age < 25 or > 75 years old
  • Radiographs demonstrating either no, little osteoarthritis, severe(bone on bone) osteoarthritis
  • Prior total or partial joint replacement surgery or surgery involving cartilage regeneration
  • Previous cortisone, PRP or Hyaluronic acid intra-articular injection within the last 3 months
  • Co-morbidity with the rheumatologic condition, inflammatory arthritis
  • Currently undergoing immunomodulatory therapy
  • Uncontrolled endocrine disorder
  • BMI >40 or joint space not visible by ultrasound
  • Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and/or hepatitis C (HCV), infection, and poorly controlled diabetes (HgA1C >7.0)
  • Pregnancy or planned pregnancy
  • previous stem cell injection into treatment joint
  • Patient scheduled to undergo any concomitant shoulder surgical procedures or other surgery which may affect outcomes.
  • Coagulopathy or anticoagulant treatment
  • Chronic pain involving multiple body parts or opioid medication management
  • Diagnosis of fibromyalgia
  • Concomitant massive(2 tendons with retraction), complete rotator cuff tendon tear
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MFAT (Micro Fragmented Adipose Tissue)Micro Fragmented Adipose TissueIntra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
Conventional TherapyCorticosteroid injectionIntra-articular injection of corticosteroid (Triamcinolone 40mg)
Primary Outcome Measures
NameTimeMethod
ASES Shoulder Score24 Months

Patient reported outcome measure that reports shoulder pain and shoulder functionality

Secondary Outcome Measures
NameTimeMethod
Veterans RAND 12 (VR-12) score24 Months

Patient reported quality of life outcome measure on a scale of 0-50 with 50 being healthy

DASH Outcome Measure24 Months

Patient reported questionnaire that measures physical function and symptoms

Trial Locations

Locations (1)

Stanford University

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath